Pharmaceutical Technology

APRIL 11, 2023

In August 2021, Zydus secured emergency use authorisation (EUA) from the Drugs Controller General of India for its Covid-19 deoxyribonucleic acid (DNA) plasmid vaccine, ZyCoV-D. The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences research executive vice-president Flavius Martin stated: “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Camargo

JULY 27, 2021

It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Additionally, gene editing allows us either to remove or to modify harmful genes. Formulation Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Drug Discovery World

OCTOBER 4, 2023

Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets. To understand the findings in humans, 350 patients with major depressive disorder (MDD) and 161 healthy controls were examined.

Research 52

Research Gene DNA Gene Expression 52

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

pharmaphorum

OCTOBER 2, 2020

Vaccibody, which is also entitled to tiered royalties on sales of any marketed products, will develop the DNA-based individualised neoantigen vaccines until the end of phase 1b. Vaccibody has been working on a targeted DNA-based vaccine platform, in a bid to find a potential new treatment paradigm for individualised cancer vaccines.

Vaccination 58

Vaccination Vaccine Immune Response Drugs 58

pharmaphorum

SEPTEMBER 29, 2020

The US drugs regulator has placed the phase 2/3 trial of INO-4800 on partial clinical hold while it seeks answers from the company about the DNA-based vaccine as well as the device used to deliver the shot to patients in the study. An expanded phase 1 trial of the shot is still ongoing and unaffected by the partial hold.

Vaccination 52

Vaccination Vaccine Trials DNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

pharmaphorum

FEBRUARY 23, 2022

Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.

Gene Therapy 105

Gene Therapy Gene Gene Sequencing Immune Response 105

Drug Discovery World

APRIL 26, 2024

In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. The vaccines are personalised to each patient after a tumour sample is removed during surgery and then analysed using DNA sequencing.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

NOVEMBER 30, 2023

The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

OCTOBER 10, 2023

Read more: First oral drug for postpartum depression approved in US The role of genetics In October, scientists discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets.

Drugs 59

Drugs Gene Expression Gene Immune Response 59

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccination 52

Vaccination Vaccine Immune Response Gene Expression 52

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 115

Vaccination Vaccine Clinical Trials Clinical Trials 115

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

pharmaphorum

MAY 11, 2021

Laronde thinks that its new class of RNA – a transcript of DNA that can be read by the body and turned into proteins – will cut the number of injections required as the body will actively make the disease-fighting protein instead of passively requiring top-ups.

RNA 98

RNA Drugs Protein Immune Response 98

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

The Pharma Data

MAY 15, 2023

The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases,” said Flavius Martin, M.D.,

DNA 40

DNA Immune Response Medicine Development 40

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

Drug Discovery World

JULY 31, 2023

Matt Hill , Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. Regardless of the type of disease targeted, at the core of biotherapy development is synthetic biology and the use of synthetic DNA to programme specific behaviours within living cells.

DNA 52

DNA Medicine Manufacturing Production 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Genome 104

Genome Genomics Medicine Development 104

Drug Discovery World

JULY 5, 2023

Protein therapeutics have been developed which bind to the checkpoint protein and “blockade” it, to prevent the moderation of the T-cell response, thus “turning up” the immune response dramatically. As part of his graduate work he invented the gel-shift or EMSA assay for the study of protein-DNA interactions.

Research 98

Research Protein Scientist Immune Response 98

Find Me Cure

OCTOBER 13, 2019

An enzyme involved in DNA repair can be the key to making chemotherapy more effective. PARP inhibitors work by blocking the function of the PARP enzyme, thus preventing the repair of the tumour DNA. This way a chemotherapy drug that damages the DNA of the cancer cells has a higher chance of succeeding at killing the cells.

Development 52

Development DNA Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 22, 2021

Lentiviral vectors have become a popular alternative for some therapies because they can deliver larger gene sequences into target cells and are less likely to stimulate an immune response in the patient that could affect their safety and efficacy. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Delveinsight

AUGUST 6, 2020

The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Drug Discovery World

FEBRUARY 28, 2024

Using a technique they’ve dubbed ‘cancer shredding’, the researchers at Gladstone Institutes, California, programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at them.

Development 64

Development Research Drugs Antibody 64

pharmaphorum

NOVEMBER 24, 2020

Another is the delivery of molecule switches to CAR-NK cells, used to activate biological pathways that can help overcome the immunosuppressive microenvironment around tumours and improve recruitment of other elements of an immune response.

Engineer 52

Engineer Immune Response DNA Genome 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Containment Immune Response Sales 40

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. ” Presentation number: 397P / Poster: ID 680. Additional information can be found at www.obipharma.com. Forward-Looking Statements.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

The Pharma Data

AUGUST 6, 2020

Early clinical results showed AstraZeneca’s candidate, AZD1222, triggered both antibody and T-cell immune responses. In addition, Inovio previously teamed up with Beijing Advaccine Biotechnology for work on its DNA vaccine candidate, INO-4800. The vaccine was moved into phase 2/3 in May.

Vaccination 52

Vaccination Vaccine Antibody Licensing 52

pharmaphorum

AUGUST 27, 2020

Conventional vaccines introduce an inactivated sample of a disease to patients with the aim of stimulating an immune response. Today researchers are attaching only a portion of the DNA or mRNA of the virus to a harmless molecule. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccination 122

Vaccination Vaccine Life Science Clinical Trials 122

Delveinsight

DECEMBER 13, 2020

Unlike a typical virus, hepatitis B’s cccDNA permanently integrates itself into a healthy cell’s DNA. HBV DNA can be integrated into the host genome. The complex nature and integration process of cccDNA contributes to the difficulties of finding a cure for hepatitis B. There are additional barriers to eliminating HBV.

Genotype 52

Genotype FDA Approval DNA Drugs 52